Detecting gut barrier dysfunction and/or cirrhosis
OwnerDavid Anderson, Huy Van +1inventors
InventorsDavid Anderson, Huy Van, Jessica Howell
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods, kits and a test strip for detecting gut barrier dysfunction and/or cirrhosis in a subject. In addition, a method of treating a subject with gut barrier dysfunction and/or cirrhosis is provided.
Claims56
A method for detecting gut barrier dysfunction and/or cirrhosis in a subject, the method comprising determining the dIgA level and mIgA level in a biological sample from the subject and a ratio thereof and comparing the ratio to a threshold.
A method for detecting gut barrier dysfunction and/or cirrhosis in a subject, the method comprising determining the dIgA1 or dIgA2 level and mIgA1 or mIgA2 level in a biological sample from the subject and a ratio thereof and comparing the ratio to a threshold.
A method for detecting gut barrier dysfunction and/or cirrhosis in a subject, the method comprising determining the level of IgA2 in a biological sample from the subject, wherein an elevated level of IgA2 compared to a threshold indicates gut barrier dysfunction and/or cirrhosis in the subject.
A method for detecting gut barrier dysfunction and/or cirrhosis in a subject, the method comprising determining the level of dIgA2 in a biological sample from the subject, wherein a level of dIgA2 that differs from a threshold indicates gut barrier dysfunction and/or cirrhosis in the subject.
A method of treating gut barrier dysfunction and/or cirrhosis in a subject, the method comprising administering the subject a treatment for gut barrier dysfunction and/or cirrhosis, wherein the subject was determined to have a gut barrier dysfunction and/or cirrhosis using a method according to any one of claims 1 to 45 or 56 to 57.
A kit for detecting gut barrier dysfunction and/or cirrhosis in a subject comprising:
- (i) an agent which binds dIgA and forms a detectable dIgA complex,
- (ii) an agent which binds mIgA and forms a detectable mIgA complex, wherein (i) binds specifically with dIgA and/or (ii) binds specifically with mIgA.
The kit of any one of clams 47 to 50, wherein one or more of the agents is bound to a solid support.
A test strip for a lateral flow device comprising at least one sample loading region, wherein
- a) the strip comprises a capture portion comprising an agent which binds dIgA, and
- b) the strip comprises a capture portion comprising an agent which binds mIgA, wherein a) is closer to the sample loading region than b) such that the sample contacts a) before.
A method for detecting gut barrier dysfunction and/or cirrhosis in a subject, the method comprising determining the dIgA level and mIgA level in a biological sample from the subject
- wherein when the mIgA level is elevated relative to a threshold, then the dIgA level is compared to a dIgA threshold wherein a difference from the dIgA threshold indicates gut barrier dysfunction and/or cirrhosis in the subject, and
- wherein when the mIgA level is decreased relative to a threshold, the ratio of the dIgA level and mIgA level is determined and compared to a ratio threshold, wherein a difference from the ratio threshold indicates gut barrier dysfunction and/or cirrhosis in the subject.
Dependencies are inferred from the claim text.